Clinical trials: Progressive Multifocal Leukoencephalopathy, open to volunteers
Progressive Multifocal Leucoencephalopathy (PML)
T-cell Therapy in Patients With PML
There is no approved standard treatment für progressive multifocal leukoencephalopathy (PML). The sponsor of the study is developing a new treatment.
- Trial name
- NCT06990087
- Testing
- Application of T-lymphocytes
- Where
- 7 sites in Germany
- Volunteers
- 23 people
- Sponsor
- Hannover Medical School
Progressive Multifocal Leukoencephalopathy, Immune Checkpoint Inhibitors
Observational Cohort Study of Chronic Viral Infection in the Central Nervous System
This research team intends to conduct a real-world cohort study of chronic CNS viral infections represented by PML, to evaluate whether administration of immune checkpoint inhibitors improves long-term outcomes in this patient…
- Trial name
- NCT07512518
- Testing
- Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Peking Union Medical College Hospital
Progressive Multifocal Leukoencephalopathy
Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study
Background: Progressive multifocal leukoencephalopathy (PML) is a rare and often fatal brain infection caused by the JC virus. The JC virus is common. More than half of adults have been exposed to it.
- Trial name
- NCT07511049
- Testing
- Brincidofovir
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Progressive Multifocal Leukoencephalopathy
Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection
This study aims to assess the efficacy and safety of pembrolizumab in immunocompromised patients with progressive multifocal leukoencephalopathy (PML).
- Trial name
- PENALTY (NCT06276504)
- Testing
- Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection
- Where
- 3 sites in France
- Volunteers
- 33 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- 2 sites in United States, Australia
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
Background: Multiple sclerosis (MS) and progressive multifocal leukoencephalopathy (PML) are disorders that affect the central nervous system (CNS). The CNS includes the brain, spinal cord, and optic nerves.
- Conditions
- Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis, Other Neuroinflammatory Diseases With BBB Leakage
- Trial name
- NCT05849467
- Testing
- 89 Zr-Df-crefmirlimab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Progressive Multifocal Leukoencephalopathy
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
Background: Progressive multifocal leukoencephalopathy (PML) is a severe viral infection of the brain. It is caused by JC virus.
- Trial name
- NCT01730131
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy
Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia
This study will evaluate the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by John Cunningham virus (JCV), among people with multiple sclerosis who have been treated with ozanimod.
- Trial name
- NCT07732907
- Testing
- Ozanimod
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb